by Jason Wasserman MD PhD FRCPC
November 19, 2026
HER2, also known as ERBB2, is a gene that drives cancer cell growth when it is overactive. HER2 is best known in breast and stomach cancer, but it is also found in a small number of colorectal cancers. Until recently, a HER2-positive result in colorectal cancer did not lead to a specific treatment. Now, two HER2-targeted treatments are approved by the US Food and Drug Administration (FDA) for HER2-positive colorectal cancer that has spread. A HER2 result can also help explain why a cancer is not responding to some other targeted drugs.
This article explains what a HER2 result means on a colorectal cancer report, how the test is done, and how the result shapes treatment decisions.
HER2 is a gene that holds the instructions for a protein called the HER2 receptor. This protein sits on the cell surface and receives signals that tell the cell to grow and divide. A healthy cell has a small amount of HER2. In some colorectal cancers, the HER2 gene is amplified, meaning extra copies are present. The cell then makes far too much HER2 protein, which sends growth signals that never switch off.
These changes in colorectal cancer are somatic, meaning they develop in the cancer cells during a person’s lifetime and are not inherited. Less often, the HER2 gene carries a mutation, a small change in the gene’s code that can switch the HER2 protein on. Amplification and mutation are different changes, and they are found and treated differently.
HER2-positive results are found in about 3% to 5% of colorectal cancers. The rate is higher, about 5% to 8%, in cancers that do not have mutations in the KRAS and NRAS genes. HER2-positive colorectal cancers share a characteristic profile:
HER2 testing in colorectal cancer is done for three main reasons:
HER2 testing in colorectal cancer is performed on tumor tissue from a biopsy or a surgically removed specimen. Three types of tests can be used: IHC, ISH, and NGS. Unlike breast and stomach cancer, colorectal cancer has no single scoring guideline that every laboratory follows.
Immunohistochemistry (IHC) uses antibodies to stain the HER2 protein on a thin slice of tumor tissue. A pathologist examines the slide and judges how strong the staining is at the cell membrane. The score runs from 0 to 3+.
Laboratories use one of two main approaches to scoring:
Your report may name the scoring system used. If it does not, your pathologist or oncologist can tell you.
In situ hybridization (ISH), including the fluorescent form called FISH, counts the copies of the HER2 gene in the cancer cells. It compares them with a control region on chromosome 17. A ratio of 2.0 or higher indicates gene amplification. ISH is usually done when the IHC score is 2+.
Next-generation sequencing (NGS) reads many genes at once. In metastatic colorectal cancer, a single NGS test often checks KRAS, NRAS, BRAF, mismatch repair, and HER2 together. NGS can find extra copies of the HER2 gene, and it can also find HER2 mutations.
NGS plays a bigger role for HER2 in colorectal cancer than in breast or stomach cancer. In the trial that led to the first colorectal approval, NGS-detected amplification in tumor tissue was one of the accepted ways to qualify. NGS can also be done on a blood sample, called a liquid biopsy. Your care team will decide whether to confirm a blood result on tissue.
HER2 results in colorectal cancer may appear in the pathology report, a separate molecular report, or both. Common results include:
A HER2-negative colorectal cancer is not expected to respond to HER2-targeted drugs. This is the most common result. Treatment is then guided by the RAS, BRAF, and mismatch repair (MMR) results and the cancer stage.
An equivocal HER2 result in colorectal cancer means the staining is borderline. ISH or NGS then decides whether the gene is amplified. If it is, the cancer is HER2-positive. If it is not, the cancer is HER2-negative.
A HER2-positive colorectal cancer is driven partly by too much HER2, and HER2-targeted drugs may help. These cancers are usually RAS- and BRAF-wildtype. That would normally make anti-EGFR drugs an option, but HER2 amplification can make those drugs less effective. Your oncologist will weigh this when planning treatment.
HER2 mutations are found in about 4% of colorectal cancers. They are studied in clinical trials, including trials of HER2-targeted drugs. The approved colorectal treatments described in this article are for HER2-positive cancer, not for HER2 mutations. Your oncologist can tell you whether a trial might be an option.
The FDA approves HER2-targeted drugs for colorectal cancer for cancer that cannot be removed with surgery or has spread, after earlier treatment. Approvals in other countries may differ. Your oncology team weighs each option alongside your RAS result, earlier treatment, and overall health.
A large trial called MOUNTAINEER-03 is testing whether tucatinib and trastuzumab work better when added to the first chemotherapy given for metastatic disease. Ask your oncologist whether you might qualify for this or other HER2 trials.
HER2 amplification matters for anti-EGFR treatment in colorectal cancer because it gives the cancer a second route for growth signals. Cetuximab and panitumumab block EGFR, but not HER2. A HER2-amplified cancer can keep growing through HER2 even while EGFR is blocked. This is why a cancer that is RAS and BRAF wild-type may still respond poorly to anti-EGFR drugs. For this reason, many oncologists check HER2 status before choosing anti-EGFR treatment.
HER2 changes in colorectal cancer develop within the cancer cells and are not inherited. A HER2 result does not show an inherited cancer risk for family members. Inherited risk for colorectal cancer is assessed in other ways, mainly through MMR testing for Lynch syndrome.
What happens after HER2 testing in colorectal cancer depends on the final result:
HER2 status can differ between the original tumor and areas of spread, or change over time. If the cancer grows or a new biopsy is taken, HER2 may be tested again, especially if an earlier result was borderline.
🔍 Search MyPathologyReport
Type what you see on your report — for example a diagnosis or test name